{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:58:02Z","timestamp":1771919882108,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["20251199"],"award-info":[{"award-number":["20251199"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32501251"],"award-info":[{"award-number":["32501251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Colloid and Interface Science"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcis.2026.140048","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:51:42Z","timestamp":1770133902000},"page":"140048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ferroptosis-sensitizing nanoprodrug system for synergistic therapy of triple-negative breast cancer"],"prefix":"10.1016","volume":"710","author":[{"given":"Yong","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaohui","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongzhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcis.2026.140048_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.jcis.2026.140048_bb0010","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"issue":"16_suppl","key":"10.1016\/j.jcis.2026.140048_bb0015","doi-asserted-by":"crossref","first-page":"10528","DOI":"10.1200\/JCO.2023.41.16_suppl.10528","article-title":"Breast cancer: global patterns of incidence, mortality, and trends","volume":"41","author":"Sedeta","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2023.151548","article-title":"Advanced triple-negative breast Cancer","volume":"40","author":"Patel","year":"2024","journal-title":"Semin. Oncol. Nurs."},{"issue":"13","key":"10.1016\/j.jcis.2026.140048_bb0025","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast Cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jcis.2026.140048_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41588-022-01047-6","article-title":"H3K27me3 conditions chemotolerance in triple-negative breast cancer","volume":"54","author":"Marsolier","year":"2022","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12_Supplement","key":"10.1016\/j.jcis.2026.140048_bb0040","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P1-10-30","article-title":"Abstract P1-10-30: pulmonary vein thrombi in metastatic breast cancer: a management dilemma","volume":"31","author":"Ahuja","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jcis.2026.140048_bb0045","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.3390\/curroncol29070378","article-title":"Triple-negative breast Cancer: a review of current curative intent therapies","volume":"29","author":"MacDonald","year":"2022","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2326-6066.CIR-23-0076","article-title":"Spatial distribution of immune cells drives resistance to neoadjuvant chemotherapy in triple-negative breast Cancer","volume":"12","author":"Donati","year":"2024","journal-title":"Cancer Immuno. Res."},{"key":"10.1016\/j.jcis.2026.140048_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108253","article-title":"Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options","volume":"237","author":"So","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"51","key":"10.1016\/j.jcis.2026.140048_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202307756","article-title":"Synergistic approach to combat triple-negative breast Cancer: B7-H4 checkpoint based photodynamic Nanoprodrug coupled with neutrophil extracellular trap regulation","volume":"33","author":"Jiang","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"15","key":"10.1016\/j.jcis.2026.140048_bb0065","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1021\/acs.nanolett.5c00488","article-title":"In situ gene engineering approach to overcome tumor resistance and enhance T cell-mediated Cancer immunotherapy","volume":"25","author":"Zhang","year":"2025","journal-title":"Nano Lett."},{"issue":"6","key":"10.1016\/j.jcis.2026.140048_bb0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","article-title":"The cell biology of ferroptosis","volume":"25","author":"Dixon","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.jcis.2026.140048_bb0075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41556-024-01425-8","article-title":"Exploiting ferroptosis vulnerabilities in cancer","volume":"26","author":"Nakamura","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"14","key":"10.1016\/j.jcis.2026.140048_bb0080","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.jcis.2026.140048_bb0085","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","article-title":"Regulation of ferroptosis by lipid metabolism","volume":"33","author":"Pope","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"12","key":"10.1016\/j.jcis.2026.140048_bb0090","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.tcb.2023.04.005","article-title":"Ferroptosis: mechanisms and implications for cancer development and therapy response","volume":"33","author":"dos Santos","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.jcis.2026.140048_bb0095","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41419-022-05121-z","article-title":"Hypoxia aggravates ferroptosis in RPE cells by promoting the Fenton reaction","volume":"13","author":"Henning","year":"2022","journal-title":"Cell Death Dis."},{"issue":"18","key":"10.1016\/j.jcis.2026.140048_bb0100","article-title":"Small Warriors of Nature: Novel Red Emissive Chlorophyllin Carbon Dots Harnessing Fenton-Fueled Ferroptosis for In Vitro and In Vivo Cancer Treatment","volume":"20","author":"Cilingir","year":"2024","journal-title":"Small"},{"issue":"7","key":"10.1016\/j.jcis.2026.140048_bb0105","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41418-022-00977-2","article-title":"BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells","volume":"29","author":"Moujalled","year":"2022","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41467-023-44412-7","article-title":"Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12943-025-02337-3","article-title":"Reprogrammed immuno-metabolic environment of cancer: the driving force of ferroptosis resistance","volume":"24","author":"Bhowmick","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2024.10.006","article-title":"Iron and siRNA co-encapsulated ferritin nanocages induce ferroptosis synergistically for cancer therapy","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.jcis.2026.140048_bb0125","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/2159-8290.CD-19-1500","article-title":"The Lipogenic regulator SREBP2 induces transferrin in circulating melanoma cells and suppresses Ferroptosis","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.jcis.2026.140048_bb0130","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/gutjnl-2022-327909","article-title":"Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade","volume":"72","author":"Conche","year":"2023","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.jcis.2026.140048_bb0135","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/pharmaceutics13111785","article-title":"Nanoparticles for Ferroptosis therapy in Cancer","volume":"13","author":"Zaffaroni","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/acsnano.2c08706","article-title":"Amplified Fenton-based oxidative stress utilizing ultraviolet Upconversion luminescence-fueled Nanoreactors for apoptosis-strengthened Ferroptosis anticancer therapy","volume":"17","author":"Nguyen","year":"2022","journal-title":"ACS Nano"},{"issue":"21","key":"10.1016\/j.jcis.2026.140048_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115789","article-title":"Therapeutic potential of 1,8-Dihydroanthraquinone derivatives for breast Cancer","volume":"24","author":"Okon","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jcis.2026.140048_bb0150","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3390\/molecules25102278","article-title":"Therapeutic emergence of Rhein as a potential anticancer drug: a review of its molecular targets and anticancer properties","volume":"25","author":"Henamayee","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jcis.2026.140048_bb0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.actbio.2024.03.030","article-title":"A multi-mode Rhein-based nano-platform synergizing ferrotherapy\/chemotherapy-induced immunotherapy for enhanced tumor therapy","volume":"180","author":"Zhu","year":"2024","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.jcis.2026.140048_bb0160","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/medicina61060981","article-title":"From nature to nanomedicine: enhancing the antitumor efficacy of Rhein, curcumin, and resveratrol","volume":"61","author":"Trofin","year":"2025","journal-title":"Medicina"},{"key":"10.1016\/j.jcis.2026.140048_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145349","article-title":"Construction of colon-specific Pickering emulsions with rhein-chitosan conjugated nanoparticles as emulsifier and its application in murine ulcerative colitis","volume":"319","author":"Niu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jcis.2026.140048_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114028","article-title":"Nanocarrier drug delivery systems for gynecological cancer therapeutics","volume":"385","author":"Berezowitz","year":"2025","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.jcis.2026.140048_bb0175","doi-asserted-by":"crossref","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","article-title":"Stimuli-responsive polymer-based Nanosystems for Cancer Theranostics","volume":"17","author":"Wei","year":"2023","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.jcis.2026.140048_bb0180","article-title":"Lymph-directed self-Immolative nitric oxide prodrug for inhibition of intractable metastatic Cancer","volume":"9","author":"Kim","year":"2022","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.jcis.2026.140048_bb0185","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1038\/s41467-024-52793-6","article-title":"Sol-moiety: discovery of a water-soluble prodrug technology for enhanced oral bioavailability of insoluble therapeutics","volume":"15","author":"Karbasi","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.jcis.2026.140048_bb0190","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41551-024-01190-x","article-title":"A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice","volume":"8","author":"Cao","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.jcis.2026.140048_bb0195","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/1061186X.2024.2383688","article-title":"Smart nanocarriers for enzyme-activated prodrug therapy","volume":"32","author":"Abo Qoura","year":"2024","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jcis.2026.140048_bb0200","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jconrel.2024.03.019","article-title":"A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors","volume":"368","author":"Nomani","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jcis.2026.140048_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108725","article-title":"Powering up targeted protein degradation through active and passive tumour-targeting strategies: current and future scopes","volume":"263","author":"Venkatesan","year":"2024","journal-title":"Pharmacol. Ther."},{"issue":"34","key":"10.1016\/j.jcis.2026.140048_bb0210","doi-asserted-by":"crossref","first-page":"30758","DOI":"10.1021\/acsnano.5c07748","article-title":"Engineering nanoparticles for gynecologic Cancer therapy","volume":"19","author":"Murray","year":"2025","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.jcis.2026.140048_bb0215","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/accountsmr.3c00094","article-title":"Beyond drug delivery system: immunomodulatory layered double hydroxide Nanoadjuvants take an essential step forward in Cancer immunotherapy","volume":"4","author":"Zhu","year":"2023","journal-title":"Acc. Mater. Res."},{"key":"10.1016\/j.jcis.2026.140048_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2026.102978","article-title":"Advanced strategies for extending the blood circulation time of nano-based delivery systems","volume":"67","author":"Kandi","year":"2026","journal-title":"Nano Today"},{"issue":"5","key":"10.1016\/j.jcis.2026.140048_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100639","article-title":"Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization","volume":"11","author":"van der Koog","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"6","key":"10.1016\/j.jcis.2026.140048_bb0230","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/med.21971","article-title":"(Nano)platforms in breast cancer therapy: drug\/gene delivery, advanced nanocarriers and immunotherapy","volume":"43","author":"Ashrafizadeh","year":"2023","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.jcis.2026.140048_bb0235","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.apsb.2021.02.019","article-title":"Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers","volume":"11","author":"Mazumdar","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jcis.2026.140048_bb0240","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jcis.2023.04.161","article-title":"Multicomponent metal-organic framework nanocomposites for tumor-responsive synergistic therapy","volume":"645","author":"Hur","year":"2023","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jcis.2026.140048_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125931","article-title":"Breaking barriers with pH-responsive nanocarriers: a new frontier in precision oncology","volume":"682","author":"Tapponi","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jcis.2026.140048_bb0250","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jcis.2020.10.103","article-title":"pH-dependent reversibly activatable cell-penetrating peptides improve the antitumor effect of artemisinin-loaded liposomes","volume":"586","author":"Yu","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jcis.2026.140048_bb0255","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ijbiomac.2022.09.157","article-title":"CD44-targeted nanoparticles with GSH-responsive activity as powerful therapeutic agents against breast cancer","volume":"221","author":"Brindisi","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jcis.2026.140048_bb0260","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2024.07.048","article-title":"Stimuli-responsive nanotheranostic systems conjugated with AIEgens for advanced cancer bio-imaging and treatment","volume":"373","author":"Oroojalian","year":"2024","journal-title":"J. Control. Release"},{"issue":"648","key":"10.1016\/j.jcis.2026.140048_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1261","article-title":"Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression","volume":"14","author":"Mao","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jcis.2026.140048_bb0270","article-title":"ROS-responsive PEGylated ferrocene polymer nanoparticles with improved stability for tumor-selective chemotherapy and imaging","volume":"22","author":"Oh","year":"2023","journal-title":"Mater. Today Bio"},{"issue":"3","key":"10.1016\/j.jcis.2026.140048_bb0275","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/acsmaterialslett.2c01093","article-title":"Matrix Metalloproteinase-2-induced morphologic transformation of self-assembled peptide Nanocarriers inhibits tumor growth and metastasis","volume":"5","author":"Cao","year":"2023","journal-title":"ACS Mater. Lett."},{"key":"10.1016\/j.jcis.2026.140048_bb0280","article-title":"Enzyme-responsive vitamin D-based micelles for paclitaxel-controlled delivery and synergistic pancreatic cancer therapy","volume":"31","author":"Peixoto","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jcis.2026.140048_bb0285","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2022.10.022","article-title":"Tailoring carrier-free nanocombo of small-molecule prodrug for combinational cancer therapy","volume":"352","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.jcis.2026.140048_bb0290","article-title":"Self-assembled peptide-derived proteolysis-targeting chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in Cancer immunotherapy","volume":"64","author":"Moon","year":"2025","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jcis.2026.140048_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121598","article-title":"A small-molecule self-assembled nanoprodrug for combination therapy of photothermal-differentiation-chemotherapy of breast cancer stem cells","volume":"286","author":"Xie","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcis.2026.140048_bb0300","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41467-023-36469-1","article-title":"Controlled sequential in situ self-assembly and disassembly of a fluorogenic cisplatin prodrug for cancer theranostics","volume":"14","author":"Wen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jcis.2026.140048_bb0305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jcis.2025.01.006","article-title":"Self-assembled doxorubicin prodrug riding on the albumin express train enable tumor targeting and bio-activation","volume":"684","author":"Hao","year":"2025","journal-title":"J. Colloid Interface Sci."},{"issue":"3","key":"10.1016\/j.jcis.2026.140048_bb0310","article-title":"Tetrasulfide bond boosts the anti-tumor efficacy of dimeric prodrug nanoassemblies","volume":"5","author":"Zuo","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"10","key":"10.1016\/j.jcis.2026.140048_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109538","article-title":"Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy","volume":"35","author":"Li","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.jcis.2026.140048_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202407833","article-title":"Concurrent amplification of Ferroptosis and immune system activation via nanomedicine-mediated radiosensitization for triple-negative breast cancer therapy","volume":"12","author":"Aishajiang","year":"2025","journal-title":"Adv. Sci."}],"container-title":["Journal of Colloid and Interface Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979726002250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979726002250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:05:26Z","timestamp":1771909526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021979726002250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"alternative-id":["S0021979726002250"],"URL":"https:\/\/doi.org\/10.1016\/j.jcis.2026.140048","relation":{},"ISSN":["0021-9797"],"issn-type":[{"value":"0021-9797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ferroptosis-sensitizing nanoprodrug system for synergistic therapy of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Colloid and Interface Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcis.2026.140048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"140048"}}